![]() In vivo, P407 hydrogels significantly reduced serum IgG levels, were biocompatible and were broken down 1 week after injection. In vitro cytotoxicity assays showed that P407 is not cytotoxic and induces no immune activation by itself. Total IgG load was gradually released within 120 h. In vitro, hydrogels showed low burst release within the first 24 h. IgG was easily incorporated in the hydrogel by simple mixing and no antibodies were lost during preparation. ![]() Release studies were optimized using the human IgG antibody. Scanning electron microscopy revealed the porous structure of the hydrogel, average pore surface was 1335 μm 2. The 25% P407 hydrogel is injectable at room temperature and depots are established quickly after subcutaneous injection. Slow release reduces systemic antibody levels and potentially mitigates the side effects of CTLA-4 therapy. ![]() Thermosensitive poloxamer 407 (P407) hydrogels were evaluated as slow release system for optimizing CTLA-4 therapy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |